BioCentury | Oct 20, 2020
Deals

Oct. 19 Quick Takes: Genesis, Genentech in AI drug discovery deal; plus Endo-BioSpecifics, Gemini, Catalyst-Jacobus, ONK, Venclexta

...the collaboration. The deal terms are undisclosed.Endo buying partner BioSpecifics  Endo International plc (NASDAQ:ENDP) is buying BioSpecifics Technologies Corp....
...value of about $540 million. The companies have had a partnership since 2004 under which BioSpecifics...
...#), ABT-199 (Compound #), GDC-0199 (Former compound #), venetoclax (Generic), Venclyxto (Other), Venclexta (Other) Endo International plc BioSpecifics Technologies Corp. Foresite...
BioCentury | Jul 22, 2020
Management Tracks

Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

...Guggenheim Securities, where she was managing director and a senior biotechnology analyst. Collagenase-based therapies company BioSpecifics Technologies Corp....
...Sawka, BioCentury Staff Biogen Inc. Rhythm Pharmaceuticals Kronos Bio Inc. ImmunoGen Inc. Akcea Therapeutics Inc. Circle Pharma Inc. Antares Pharma Inc. Krystal Biotech Inc. BioSpecifics Technologies Corp. Cradle...
BioCentury | May 14, 2020
Management Tracks

Jakob Dupont steps down as CMO of Gossamer; plus Ascendis, Seer, Jazz, Dragonfly and more

...was SVP and head of clinical development at PTC Therapeutics Inc. (NASDAQ:PTCT). Collagenase-based therapy company BioSpecifics Technologies Corp....
...Pharma A/S Seer Inc. Jazz Pharmaceuticals plc Dragonfly Therapeutics Inc. Caribou Biosciences Inc. Bolt Biotherapeutics Inc. BioDelivery Sciences International Inc. Aruvant Sciences Inc. BioSpecifics Technologies Corp....
BioCentury | Apr 14, 2020
Management Tracks

Kelly joins CytoDyn as CMO amid COVID-19 trials; plus Antengene, Genetron, Bolt, BioSpecifics, CMAB and more

...it began enrolling patients with severe symptoms in a Phase IIb/III trial. Collagenase-based therapies company BioSpecifics Technologies Corp....
...of corporate affairs and finance, will become interim CFO. Robin Sawka, BioCentury Staff CytoDyn Inc. Antengene Corp. Bolt Biotherapeutics Inc. BioSpecifics Technologies Corp. CMAB...
BioCentury | Apr 11, 2020
Management Tracks

Harpal Kumar named president of Grail Europe; plus Notable, Oncoceutics, ReAlta, Parker Institute

...Health Inc. (NASDAQ:GHDX). Robin Sawka, BioCentury Staff Grail Inc. Notable Labs Inc. Oncoceutics Inc. Parker Institute for Cancer Immunotherapy Bolt Biotherapeutics Inc. BioSpecifics Technologies Corp. CMAB...
BioCentury | Apr 10, 2020
Management Tracks

Shakeup at Arix; plus Emergent, AlloVir, Asklepios Bio, Morphic, Gritstone and more

...B.V. Seres Therapeutics Inc. Dynamk Capital Polyneuron Pharmaceuticals AG Vor Biopharma Inc. Prime Therapeutics LLC Oncoceutics Inc. Exicure Inc. ObsEva S.A. Acacia Pharma Group plc BioSpecifics Technologies Corp. Bolt...
BioCentury | Oct 10, 2019
Company News

Management tracks: Galderma taps new leadership from Shire; plus iOmx, BioSpecifics, Poseida, Kedalion, GenSight, Lyra, Verrica and Mizuho

...Aratana Therapeutics Inc. (NASDAQ:PETX), was appointed chairman, while Sofinnova Partners’ Henrijette Richter becomes vice chairman. BioSpecifics Technologies Corp....
...and biotechnology companies. He was a senior analyst at Credit Suisse. Jonathan Block, Associate Editor iOmx Therapeutics AG BioSpecifics Technologies Corp. Poseida...
BioCentury | Apr 20, 2017
Clinical News

Xiaflex: Ph I started

...exclusive, worldwide rights to the product for 8 indications, including Dupuytren’s contracture and Peyronie’s disease. BioSpecifics...
...rights to additional indications, but has not yet opted in to the uterine fibroids indication. BioSpecifics Technologies Corp....
...collagen content and stiffness of treated fibroids Status: Phase I started Milestone: NA Julian Zhu collagenase clostridium histolyticum Xiaflex Xiapex BioSpecifics Technologies Corp. Endo...
BioCentury | Dec 1, 2016
Clinical News

Xiaflex: Ph IIa data

...to treat Peyronie’s disease. Endo has exclusive, worldwide rights to the product from BioSpecifics Technologies. BioSpecifics Technologies Corp....
...satisfaction with treatment and composite responder analysis Status: Phase IIa data Milestone: NA Alicia Parker collagenase clostridium histolyticum Xiaflex Xiapex BioSpecifics Technologies Corp. Endo...
BioCentury | Feb 22, 2016
Clinical News

Xiaflex: Phase IIb started

...contracture and Peyronie’s disease. Endo has exclusive, worldwide rights to the product from BioSpecifics Technologies. BioSpecifics Technologies Corp....
Items per page:
1 - 10 of 243
BioCentury | Oct 20, 2020
Deals

Oct. 19 Quick Takes: Genesis, Genentech in AI drug discovery deal; plus Endo-BioSpecifics, Gemini, Catalyst-Jacobus, ONK, Venclexta

...the collaboration. The deal terms are undisclosed.Endo buying partner BioSpecifics  Endo International plc (NASDAQ:ENDP) is buying BioSpecifics Technologies Corp....
...value of about $540 million. The companies have had a partnership since 2004 under which BioSpecifics...
...#), ABT-199 (Compound #), GDC-0199 (Former compound #), venetoclax (Generic), Venclyxto (Other), Venclexta (Other) Endo International plc BioSpecifics Technologies Corp. Foresite...
BioCentury | Jul 22, 2020
Management Tracks

Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

...Guggenheim Securities, where she was managing director and a senior biotechnology analyst. Collagenase-based therapies company BioSpecifics Technologies Corp....
...Sawka, BioCentury Staff Biogen Inc. Rhythm Pharmaceuticals Kronos Bio Inc. ImmunoGen Inc. Akcea Therapeutics Inc. Circle Pharma Inc. Antares Pharma Inc. Krystal Biotech Inc. BioSpecifics Technologies Corp. Cradle...
BioCentury | May 14, 2020
Management Tracks

Jakob Dupont steps down as CMO of Gossamer; plus Ascendis, Seer, Jazz, Dragonfly and more

...was SVP and head of clinical development at PTC Therapeutics Inc. (NASDAQ:PTCT). Collagenase-based therapy company BioSpecifics Technologies Corp....
...Pharma A/S Seer Inc. Jazz Pharmaceuticals plc Dragonfly Therapeutics Inc. Caribou Biosciences Inc. Bolt Biotherapeutics Inc. BioDelivery Sciences International Inc. Aruvant Sciences Inc. BioSpecifics Technologies Corp....
BioCentury | Apr 14, 2020
Management Tracks

Kelly joins CytoDyn as CMO amid COVID-19 trials; plus Antengene, Genetron, Bolt, BioSpecifics, CMAB and more

...it began enrolling patients with severe symptoms in a Phase IIb/III trial. Collagenase-based therapies company BioSpecifics Technologies Corp....
...of corporate affairs and finance, will become interim CFO. Robin Sawka, BioCentury Staff CytoDyn Inc. Antengene Corp. Bolt Biotherapeutics Inc. BioSpecifics Technologies Corp. CMAB...
BioCentury | Apr 11, 2020
Management Tracks

Harpal Kumar named president of Grail Europe; plus Notable, Oncoceutics, ReAlta, Parker Institute

...Health Inc. (NASDAQ:GHDX). Robin Sawka, BioCentury Staff Grail Inc. Notable Labs Inc. Oncoceutics Inc. Parker Institute for Cancer Immunotherapy Bolt Biotherapeutics Inc. BioSpecifics Technologies Corp. CMAB...
BioCentury | Apr 10, 2020
Management Tracks

Shakeup at Arix; plus Emergent, AlloVir, Asklepios Bio, Morphic, Gritstone and more

...B.V. Seres Therapeutics Inc. Dynamk Capital Polyneuron Pharmaceuticals AG Vor Biopharma Inc. Prime Therapeutics LLC Oncoceutics Inc. Exicure Inc. ObsEva S.A. Acacia Pharma Group plc BioSpecifics Technologies Corp. Bolt...
BioCentury | Oct 10, 2019
Company News

Management tracks: Galderma taps new leadership from Shire; plus iOmx, BioSpecifics, Poseida, Kedalion, GenSight, Lyra, Verrica and Mizuho

...Aratana Therapeutics Inc. (NASDAQ:PETX), was appointed chairman, while Sofinnova Partners’ Henrijette Richter becomes vice chairman. BioSpecifics Technologies Corp....
...and biotechnology companies. He was a senior analyst at Credit Suisse. Jonathan Block, Associate Editor iOmx Therapeutics AG BioSpecifics Technologies Corp. Poseida...
BioCentury | Apr 20, 2017
Clinical News

Xiaflex: Ph I started

...exclusive, worldwide rights to the product for 8 indications, including Dupuytren’s contracture and Peyronie’s disease. BioSpecifics...
...rights to additional indications, but has not yet opted in to the uterine fibroids indication. BioSpecifics Technologies Corp....
...collagen content and stiffness of treated fibroids Status: Phase I started Milestone: NA Julian Zhu collagenase clostridium histolyticum Xiaflex Xiapex BioSpecifics Technologies Corp. Endo...
BioCentury | Dec 1, 2016
Clinical News

Xiaflex: Ph IIa data

...to treat Peyronie’s disease. Endo has exclusive, worldwide rights to the product from BioSpecifics Technologies. BioSpecifics Technologies Corp....
...satisfaction with treatment and composite responder analysis Status: Phase IIa data Milestone: NA Alicia Parker collagenase clostridium histolyticum Xiaflex Xiapex BioSpecifics Technologies Corp. Endo...
BioCentury | Feb 22, 2016
Clinical News

Xiaflex: Phase IIb started

...contracture and Peyronie’s disease. Endo has exclusive, worldwide rights to the product from BioSpecifics Technologies. BioSpecifics Technologies Corp....
Items per page:
1 - 10 of 243